Visum Pharma
VISUMPharma Inc. is dedicated to developing therapeutics for diseases with significant unmet medical needs by leveraging novel insights into their pathogenesis. The company focuses on normalizing activity of key signaling nodes that serve as tipping points in disease processes, aiming to create large-market, impactful, and innovative drug solutions. Their research spans neurodegenerative diseases like Alzheimer’s and ALS, as well as oncology, with a mission to unlock new therapies through unexplored pathways.
Industries
Nr. of Employees
small (1-50)
Visum Pharma
Products
Alzheimer's disease therapeutic program
Preclinical program developing pharmacological approaches to reduce microglial activation and prevent synaptic loss in Alzheimer's disease and related neurodegenerative conditions.
Amyotrophic lateral sclerosis (ALS) therapeutic program
Discovery program exploring cellular signaling abnormalities in ALS to develop broadly acting therapeutics that target downstream, convergent disease mechanisms.
Oncology discovery program targeting LIN28
Preclinical discovery efforts to downregulate LIN28 and modulate associated microRNA networks to reduce tumor stemness, therapy resistance, and metastasis risk.
Alzheimer's disease therapeutic program
Preclinical program developing pharmacological approaches to reduce microglial activation and prevent synaptic loss in Alzheimer's disease and related neurodegenerative conditions.
Amyotrophic lateral sclerosis (ALS) therapeutic program
Discovery program exploring cellular signaling abnormalities in ALS to develop broadly acting therapeutics that target downstream, convergent disease mechanisms.
Oncology discovery program targeting LIN28
Preclinical discovery efforts to downregulate LIN28 and modulate associated microRNA networks to reduce tumor stemness, therapy resistance, and metastasis risk.
Expertise Areas
- Neuroscience drug discovery
- Neuroinflammation and microglia biology
- Translational models for neurodegeneration
- Oncology target modulation (LIN28/microRNA axis)
Key Technologies
- Small-molecule therapeutics discovery
- Target identification and validation
- Microglia modulation
- MicroRNA pathway modulation